Chinese Plant Protein Product Infringes Patent, Says Fed. Cir.

The Federal Circuit sided with Colorado’s Ventria Bioscience Inc. in holding that a Chinese rival’s imports of clinical grade rice-derived, recombinant human serum albumin, or rHSA, products infringe a Ventria patent, affirming a trade agency’s decision.

Wuhan Healthgen Biotechnology Corp. was barred by the US International Trade Commission in late 2022 from importing its higher-grade albumin product until a Ventria patent expires in 2030. Healthgen appealed the ruling and argued to the US Court of Appeals for the Federal Circuit that its product clumped together during the its transit from China to the US to such an extent that it ...